@article{article, title  = {{Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/s2352-3026(24)00249-7 }},

 year = {{2024}},

 month = {{9}},

 author = {{Cook G and Ashcroft AJ and Senior E and Olivier C and Hockaday A and Richards J and Cavenagh JD and Snowden JA and Drayson MT and de Tute R and Roberts L et al}},

 doi = {{10.1016/s2352-3026(24)00249-7}},

 journal = {{The Lancet Haematology}},

 pages = {{S2352-3026(24)00249}},

 note = {{Accessed on 2024/12/28}}}